This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06945419 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 219 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Healthy; Overweight; Obesity; Type 2 Diabetes |
| Interventions | LY4086940; Placebo; LY4086940 |
| Start | Apr 23, 2025 |
| Primary completion | Aug 5, 2026 |
| Study completion | Aug 5, 2026 |
| Results posted | Not yet |
| Registry last updated | Aug 19, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.
Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Baseline up to Week 9 |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of LY4086940
More from Eli Lilly and Company
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881432)
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased (Phase 3 NCT07900633)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- RENEW-MDD 1: Brenipatide, Phase 3 (NCT07412756)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
